Holen Sie sich die Stockscreener-App
72.10
0.04%
-0.03
Handel nachbörslich:
72.06
-0.04
-0.06%
Schlusskurs vom Vortag:
$72.13
Offen:
$72.15
24-Stunden-Volumen:
2.81M
Relative Volume:
0.63
Marktkapitalisierung:
$10.86B
Einnahmen:
$10.73M
Nettoeinkommen (Verlust:
$-455.74M
KGV:
-20.27
EPS:
-3.5569
Netto-Cashflow:
$-502.70M
1W Leistung:
-0.04%
1M Leistung:
+0.78%
6M Leistung:
+145.57%
1J Leistung:
+131.24%
1-Tages-Spanne:
$72.00
$72.16
1-Wochen-Bereich:
$72.00
$72.19
52-Wochen-Spanne:
$21.51
$72.61
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
3020 CALLAN ROAD, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
72.10 | 10.87B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Roth Capital | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-06-11 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-09-24 | Eingeleitet | Goldman | Buy |
| 2024-08-28 | Eingeleitet | Barclays | Overweight |
| 2024-05-03 | Eingeleitet | BofA Securities | Buy |
| 2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
| 2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-17 | Eingeleitet | Needham | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | Cowen | Outperform |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
The Technical Signals Behind (RNA) That Institutions Follow - Stock Traders Daily
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Is Avidity Biosciences Inc a good long term investmentStock Price Divergence & Market Monitoring and Alerts - earlytimes.in
Is Avidity Biosciences Inc. stock resilient to inflationSupport Zone Identification & High Return Trading Ideas - bollywoodhelpline.com
CEO Moves: Is Avidity Biosciences Inc stock a buy on dipsSwing Trade & Weekly High Return Opportunities - moha.gov.vn
Novartis to acquire Avidity Biosciences for about $12 billion - MSN
Assenagon Asset Management S.A. Has $2 Million Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
How Avidity Biosciences Inc. stock valuations compare to rivalsQuarterly Market Summary & Risk Adjusted Buy/Sell Alerts - Улправда
Avidity Biosciences Earnings Notes - Trefis
Exit Recap: Is Avidity Biosciences Inc. stock resilient to inflationJuly 2025 Spike Watch & Long-Term Growth Plans - ulpravda.ru
Avidity Biosciences stock hits all-time high at 72.23 USD By Investing.com - Investing.com South Africa
Avidity Biosciences stock hits all-time high at 72.23 USD - Investing.com
Officer Calderaro III Surrenders 9,726 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer Flanagan Surrenders 13,695 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer Mosbrooker Surrenders 47,990 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer Gallagher Surrenders 41,366 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer McCarthy Acquires 21,702 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Avidity Biosciences (NASDAQ:RNA) Lowered to Hold Rating by Evercore ISI - MarketBeat
Will Avidity Biosciences Inc. stock gain from strong economy2025 Institutional Moves & Technical Buy Zone Confirmation - DonanımHaber
RNA SEC FilingsAvidity Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Avidity Biosciences receives FTC clearance for Novartis merger - MSN
Avidity reports FTC granted request for early termination of HSR waiting period - MSN
Novartis-Avidity Biosciences deal gets early clearance in US - MLex
Evercore ISI Downgrades Avidity Biosciences to In Line From Outperform, Adjusts Price Target to $72 From $65 - marketscreener.com
Avidity Biosciences Receives FTC Clearance for Novartis Merger - TipRanks
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week HighHere's Why - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Mirador Capital Partners LP Purchases 22,666 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Top 2 Health Care Stocks That May Keep You Up At Night In December - Benzinga
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity - MSN
Frazier Life Sciences Management L.P. Has $17.75 Million Stock Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Reaches New 52-Week HighWhat's Next? - MarketBeat
EcoR1 Capital LLC Sells 57,576 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences stock hits all-time high at 71.81 USD By Investing.com - Investing.com Australia
Avidity Biosciences stock hits all-time high at 71.81 USD - Investing.com
Aug Closing: Is Avidity Biosciences Inc stock vulnerable to regulatory risksTrade Performance Summary & Growth-Oriented Investment Plans - moha.gov.vn
Avoiding Lag: Real-Time Signals in (RNA) Movement - news.stocktradersdaily.com
Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger - MSN
Assessing Avidity Biosciences (RNA) Valuation After a 130% Year-to-Date Share Price Surge - Yahoo Finance
Dyne stock upgraded at Oppenheimer (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says - marketscreener.com
Norges Bank Makes New Investment in Avidity Biosciences, Inc. $RNA - MarketBeat
Franklin Resources Inc. Sells 29,465 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
JPMorgan Chase & Co. Buys 139,473 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences stock hits all-time high at 71.78 USD By Investing.com - Investing.com South Africa
Avidity Biosciences stock hits all-time high at 71.78 USD - Investing.com
Why Avidity Biosciences Inc. stock could benefit from AI revolution2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - Newser
Avidity Biosciences, Inc. (RNA): A Bull Case Theory - Finviz
Schroder Investment Management Group Raises Stake in Avidity Biosciences, Inc. $RNA - MarketBeat
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):